Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 139Lymphoid 60Other hematologic neoplasm 41Genitourinary 8Gastrointestinal 6Myeloid 5CNS 5Tumor-Agnostic 4Other solid neoplasm 4Dermatologic 4Sarcoma 3Breast 3Thoracic 2Head & Neck 2Gynecologic 1Endocrine 1Classical hematology 1

Conditions

Multiple Myeloma 1Anemia 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 8Mycophenolic Acid 8Cyclosporine 8Cyclophosphamide 7Tacrolimus 5Filgrastim 5Cytarabine 5Carboplatin 4Azacitidine 4olaparib 3Thiotepa 3Lenalidomide 3Etoposide 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3venetoclax 2tipifarnib 2sargramostim 2peginesatide 2laromustine 2hematide 2enasidenib 2alvocidib 2aldesleukin 2Vorinostat 2Tretinoin 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Dexamethasone × Classical hematology × Clear all
NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Classical hematologyPlasma cell

Anemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡